“This collaboration brings to market a cleaner, more sustainable, and more reliable source of inositols. As essential compounds, inositols play critical roles in hormonal balance, reproductive health, infant brain development, blood sugar regulation with improved insulin sensitivity, and overall metabolic health” said Jerry Whelan, Senior Vice President, Food & Nutrition at LBBS. “DMC leverages their proprietary precision fermentation technology to produce bio-identical ingredients without solvents, with greater purity and consistency, and with a significantly lower environmental footprint than traditional chemical production methods”.

“Together, LBBS and DMC are shaping the future of ingredient innovation,” said Rusty Pittman, Vice President of Business Development at DMC. “This partnership underscores our shared commitment to high-purity, naturally derived ingredients with proven health benefits – responsibly sourced and sustainably produced. The partnership further strengthens LBBS’s growing portfolio of functional and sustainable ingredient technologies that empower brands to meet the next generation of consumer expectations, without compromising performance, purity, or planet.

For more information about DMC’s KeyPura™ fermented inositols, please contact LBB Specialties today.

About LBB Specialties
LBB Specialties is a dedicated provider of specialty chemicals and ingredients, specializing in sales, marketing, and distribution across North America. We provide technical solutions with a customer-first approach, serving diverse end-markets through five industry and market business units: Care, Food & Nutrition, Industrial Specialties, Life Sciences, and Canada. www.LBBSpecialties.com

Media Contact:
Ahmed Hanafy
media@lbbspecialties.com

About DMC
DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company’s proprietary platform, Dynamic Metabolic Control™, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.

Media Contact:
media@dmcbio.com

The post LBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. Market appeared first on DMC Biotechnologies.

BOULDER, CO — July 15, 2025 — DMC Biotechnologies (DMC), a leading U.S.-based biomanufacturer, announces the commercial launch of D-chiro-inositol. This new ingredient joins DMC’s growing portfolio of sustainable health actives, produced through fermentation, and now available for health-forward nutraceutical brands in the U.S.

Elevating the Standard Through Fermentation

DMC’s D-chiro-inositol is produced through a proprietary precision fermentation that is solvent-free, has a higher assurance of purity, and is significantly more sustainable than the incumbent process.

“We’re proud to introduce fermented D-chiro-inositol as a next generation ingredient for brands committed to clean and sustainable products” said Rusty Pittman, VP of Business Development at DMC. “In addition, consumers increasingly care how products are made—with fermentation emerging as a preferred alternative to chemical processing.”

D-Chiro-Inositol is a Key Ingredient for Supplements Targeting Metabolic Health and Ovarian Function

D-chiro-inositol is a naturally occurring isomer of inositol that is a popular ingredient in women’s health supplements and is often chosen to support menstrual, ovarian, and hormonal health, as well as maintain healthy insulin levels.¹ D-chiro-inositol also has emerging applications in men’s health supplements. For instance, a recent clinical study showed D-chiro-inositol increased serum testosterone level in men by 23%.²

Building a Nutraceutical Portfolio and Sustainable Future

“The launch of D-chiro-inositol builds on the momentum of our recent introduction of myo-inositol,” said Jim Flatt, CEO of DMC. “Together, these products demonstrate DMC’s ability to quickly develop and commercialize important and sustainable human nutritional ingredients. We’re continuing to expand our pipeline of nutraceutical and cosmetic actives—bringing the same quality, transparency, and environmental responsibility to every product we introduce.”

This milestone supports DMC’s mission to decarbonize global supply chains and promote better health and wellness through cleaner and more sustainable ingredients.

The Complementary Roles of Myo-Inositol and D-Chiro-Inositol

Clinical trials suggest myo-inositol and D-chiro-inositol are more effective when formulated together, in various supplement applications that support menstrual, ovarian, and hormonal health. With both now available from DMC, nutraceutical brands can offer complete solutions utilizing our cleaner and more sustainable ingredients.

D-chiro-inositol is available for commercial use in the U.S. and select international markets.

To learn more about DMC Biotechnologies and its commitment to sustainable, high-performance ingredients, visit www.dmcbio.com.

Media Contact:
media@dmcbio.com

About DMC
DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company’s proprietary platform, Dynamic Metabolic Control™, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.

1. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease. The views and nutritional advice expressed by DMC Biotechnologies are not intended to be a substitute for conventional medical services.
2. Giovanni Monastra, et al. June 3, 2021, Volume 31, Issue 1, Article 13, Basic Clinical Andrology “D-chiro-inositol, an aromatase down-modulator, increases androgens and reduces estrogens in male volunteers: a pilot study.”

The post DMC Debuts Industry-First Fermented D-Chiro-Inositol appeared first on DMC Biotechnologies.

“Toyobo is dedicated to driving innovations in sustainable materials and production,” said Iizuka Norio, Executive Officer, Sustainability and Corporate Planning Division at Toyobo. “By integrating Toyobo’s chemical synthesis and biotechnology expertise with DMC’s advanced biotechnology platform, we aspire to create new opportunities for sustainable chemical products that meet global market demands.”

Through this agreement, the two companies will leverage their complementary capabilities to accelerate the development and commercialization of bio-based and affordable chemical products. DMC will utilize its proprietary Dynamic Metabolic Control™ technology and metabolic engineering expertise to enable cost-advantaged, efficient, scalable and robust fermentation processes, while Toyobo will leverage its extensive expertise in both chemical synthesis and biotechnology, along with its deep industry knowledge, to bring these innovative products to market.

“We are excited to partner with Toyobo, a company with a long history of leadership in chemical innovation,” said Jim Flatt, CEO of DMC Biotechnologies. “This collaboration reflects our shared commitment to delivering sustainable, cost-effective solutions to the chemical industry. It also highlights how established industry leaders and innovative technology companies can come together to meet the moment—advancing more sustainable and secure supply chains for essential chemical products.”

To learn more about DMC Biotechnologies and its commitment to sustainable, high-performance ingredients, visit www.dmcbio.com.

Media Contact:
media@dmcbio.com

About DMC
DMC Biotechnologies, Inc. is a U.S. biomanufacturer transforming how the world makes chemicals. The company leverages precision fermentation and synthetic biology to decarbonize chemicals, deliver more sustainable and naturally produced food ingredients and supplements, and improve the security of global supply chains. DMC’s proprietary platform technology, Dynamic Metabolic Control™, simplifies biology and enables predictable, robust, and more efficient fermentation.

The post Toyobo and DMC Sign JDA to Advance Sustainable Chemical Solutions appeared first on DMC Biotechnologies.

Her appointment comes as DMC enters a critical phase of commercial expansion and launches its Series C fundraising round to support full-scale production and sales growth of its first products.

“K’Lynne’s track record in scaling breakthrough technologies and shaping strategy across both startups and global enterprises makes her an ideal leader for our board,” said Jim Flatt, CEO of DMC. “Her guidance will be pivotal as we commercialize products from our biomanufacturing technology platform, expand our customer base, and deliver sustainable solutions at scale.”

Johnson was the founding CEO of Elevance Renewable Sciences, a specialty chemicals company leveraging renewable feedstock. She also held senior leadership roles at Innovene, BP, and Amoco Corporation. In addition to her new role at DMC, Johnson currently serves on the boards of FMC Corporation, Trinseo Corporation, JM Huber Corporation, and BlueScope Steel Limited.

“DMC has built a powerful technology platform with real commercial momentum,” said Johnson. “I’m excited to help the team bring sustainable, scalable alternatives to market and drive meaningful change in the chemical industry.”

DMC’s Series C round will fuel market launches and sales growth of DMC’s first products in the nutrition, personal care and bio-based materials industries, expanding its customer base and chemicals partnerships, and supporting the company in scaling product manufacture.

To learn more about DMC Biotechnologies and its commitment to sustainable, high-performance ingredients, visit www.dmcbio.com.

Media Contact:
media@dmcbio.com

About DMC
DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company’s proprietary platform, Dynamic Metabolic Control™, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.

The post DMC Biotechnologies Appoints Industry Veteran K’Lynne Johnson as Chair of the Board appeared first on DMC Biotechnologies.

Elevating the Standard Through Fermentation

DMC’s fermentation-derived myo-inositol is produced through a natural, solvent-free process that ensures superior purity and reduces environmental impact. Traditional chemical synthesis of myo-inositol uses harsh chemical processes, feedstock more susceptible to impurities, and significant energy for refining. Fermented myo-inositol meets the increasing demand from consumers, brands, and formulators for clean-label, responsibly sourced ingredients.

“We’re proud to introduce a cleaner, more sustainable source of myo-inositol—an essential nutrient that supports glucose management, reproductive health, and infant development,” said Rusty Pittman, VP of Business Development at DMC. “Fermented myo-inositol is more naturally produced, better for the environment and offers higher assurance of purity and consistent quality – important benefits for all health ingredients. We are particularly grateful to the leading brands that supported this initiative with valuable product insights and early supply commitments.”

Building a Nutraceutical Portfolio and Sustainable Future

“Myo-inositol marks DMC’s entry into the nutraceutical space,” said Jim Flatt, CEO of DMC. “We’re excited to follow it with a second ingredient later this year—the beginning of a broader portfolio of nutraceutical and cosmetic actives we are building. These two product introductions are clear examples of DMC’s ability to meet the growing market demand for sustainable products in a timely and cost-efficient manner.”

This launch is aligned with DMC’s mission to deliver naturally produced, cleaner ingredients and sustainable chemicals that decarbonize and secure supply chains and do so with economic viability.

A Critical Nutrient for Human Health

Myo-inositol, a naturally occurring sugar in the human body, plays a key role in cell signaling, insulin response, and neurotransmitter function, making it essential across various life stages and health conditions. With significant growth across key dietary supplement, infant nutrition, and functional food markets, a naturally produced, cleaner, and sustainable source of myo-inositol is more important than ever.

Myo-Inositol Provides Clinically Proven Health and Wellness Benefits

Metabolic Health
Supports insulin signaling and glucose metabolism, aiding in conditions like insulin resistance, type 2 and gestational diabetes, and metabolic syndrome.

Reproductive Health
Used in fertility and women’s health formulations to support hormonal balance, ovulation, and egg quality—especially for those with polycystic ovary syndrome (PCOS).

Infant Nutrition
Found naturally in breast milk, myo-inositol is a required ingredient in infant formula and is believed to support infant brain development and neurotransmitter function.

To learn more about DMC Biotechnologies and its commitment to sustainable, high-performance ingredients, visit www.dmcbio.com.

Media Contact:
media@dmcbio.com

About DMC
DMC is a U.S.-based biomanufacturer redefining how the world produces chemicals. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance ingredient quality, and strengthen global supply chain resilience. The company’s proprietary platform, Dynamic Metabolic Control™, simplifies biological processes to enable predictable, scalable, and highly efficient fermentation—unlocking a new era of low-impact chemical manufacturing.

The post DMC Launches Fermented Myo-Inositol — A Cleaner and More Sustainable Alternative appeared first on DMC Biotechnologies.

Dr. Flatt brings more than 30 years of leadership experience in biotechnology and biomanufacturing. He has a proven track record of delivering commercial success through innovation, building partnerships, and scaling operations. His previous roles include co-founder and CEO of Brightseed, where he led the development of the Forager AI platform for discovery, development and commercialization of novel bioactive health ingredients, and senior leadership positions at Hampton Creek, Synthetic Genomics, and Martek Biosciences.

Dr. Flatt’s breadth of expertise will guide DMC through its next phase of growth, scaling operations and commercializing various nutraceutical ingredients and sustainable chemicals.

“Jim is an exceptional leader with a significant track record of developing and commercializing innovative biotechnology-based products,” said Matt Lipscomb, Founder and Board Member of DMC Biotechnologies. “I am confident in his ability to take DMC to new heights, and I look forward to supporting him in his new role.”

DMC is a leading U.S. biomanufacturer with a proprietary platform, Dynamic Metabolic Control™, which enables a more scalable and efficient fermentation process. The company is leveraging this novel technology to develop a portfolio of sustainable and supply-chain secure chemicals and ingredients.

“Jim’s deep expertise in leading teams and strong track record in commercializing numerous biotechnology-based products across multiple industries will be instrumental for DMC’s next commercial phase.” said Rob van der Meij, Chairman of the Board of DMC Biotechnologies and Managing Partner of Capricorn Partners. “Under his leadership, we will expand our operational capabilities and drive the launch of several new products leveraging DMC’s proprietary technology.”

Dr. Flatt holds a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison and degrees from MIT and UC Berkeley. As a recognized innovator, he holds more than a dozen patents and has been honored with numerous industry awards for innovation and leadership.

“I am honored to join DMC Biotechnologies as CEO,” said Dr. Flatt. “The company is uniquely positioned at the forefront of sustainable biomanufacturing, and I look forward to working with the talented team to scale our operations and commercialize impactful solutions that address critical challenges in global supply chains, health, and the environment.” DMC’s Dynamic Metabolic Control™ technology platform enables the development of economically advantaged bioprocesses with high yield of the desired product, addressing the persistent cost barrier that’s limited the deployment of more biomanufacturing processes.”

To learn more about DMC Biotechnologies and its pioneering approach to sustainable ingredient production, visit www.dmcbio.com.

DMC media contact:
media@dmcbio.com

About DMC
DMC is a U.S. biomanufacturer seeking to transform how the world makes chemicals. The company leverages precision fermentation and synthetic biology to decarbonize chemicals, deliver more sustainable and natural food ingredients and supplements, and improve the security of global supply chains. It’s platform technology, Dynamic Metabolic Control™, simplifies biology, and enables predictable, robust, and more efficient fermentation.

The post Dr. Jim Flatt Announced as New CEO of DMC Biotechnologies appeared first on DMC Biotechnologies.

PARIS, FRANCE (June 12, 2024) – Two major French industrial leaders Danone and Michelin, the American start-up DMC Biotechnologies and Crédit Agricole Centre France, a key investor in the region, have agreed to create the Biotech Open Platform to bolster the development of advanced fermentation processes, particularly precision fermentation, on a larger scale. Precision fermentation is a revolutionary biotechnological process to produce bio-based materials and ingredients.

With an investment of over 16 million euro in the first phase, the industrial and technological platform will be located in Clermont-Ferrand within the Parc Cataroux Center for Sustainable Materials, an innovation accelerator supported by Michelin. The Biotech Open Platform is also supported by several public and private institutions: the University of Clermont Auvergne, the company Greentech, the Auvergne-Rhône-Alpes Region under the European Regional Development Fund (ERDF) and Clermont Auvergne Métropole.

As industry looks for alternatives to fossil-based resources, it is turning to innovative and sustainable solutions to meet its supply needs while providing more efficient materials. Biotechnology – and particularly precision fermentation – is one of the most promising ways to meet this challenge. Precision fermentation is a cutting-edge technology that uses microorganisms like bacteria, yeast or fungi to produce proteins, enzymes and other molecules that are used in industry. It is particularly suited to innovation in the agri-food and materials sectors. Although fundamental research has made considerable progress, biotechnologies must now be developed on a larger scale.

The Biotech Open Platform’s ambition is to accelerate the development of precision fermentation by enabling the scale-up of innovative products and processes already tested in the laboratory. By 2025, the project plans to install an initial demo-scale production line, including a fermenter and purification equipment. Additional equipment will be installed in the following years, including a second production line. This ramp-up will enable the platform to meet the scale-up needs of its founders and to gradually open it up to other companies facing the challenge of scaling up in the industrial biomanufacturing sector.

Florent Menegaux, President of the Michelin group: “ The Michelin group is pleased to announce the creation, with its partners, of the Biotech Open Platform – a unique tool that will enhance the development of bio-sourced materials, a key challenge for the industry of tomorrow. Located in Auvergne, it exemplifies Michelin’s unflagging commitment to developing innovation and the regions where the Group operates.”

Antoine de Saint-Affrique, CEO of Danone: “At Danone, we have always been focused on investing in the future of food, and this partnership is the next step in this journey. We look forward to working with our partners to develop cutting-edge fermentation technologies which will accelerate innovation, health benefits and decarbonization in the food industry. We are proud to be part of this collective effort and to strengthen our contribution to meet the challenges facing the industry today.”

Kenny Erdoes, CEO of DMC: “We are enthusiastic about this new partnership with companies that are at the heart of French life. For us, as an American start-up, the development of the new Biotech Open Platform will enable us to accelerate the scale-up and commercialization of new products leveraging our transformative fermentation technology.”

Frédéric Baraut, CEO of Crédit Agricole Centre France: “Crédit Agricole Centre France is taking steps to support transformation and innovation in the region. By contributing to the Biotech Open Platform, we are helping to develop a new bio-based sector based in Clermont-Ferrand and also adding to the value and the attractiveness of the region. This will also help provide opportunities and synergies to the start-ups in our Innovation Village, also in the Parc Cataroux.”

Press contacts:

Michelin / Center for Sustainable Materials:
Pascale Audibert
pascale.audibert@michelin.com
+336 34 09 82 67
Michelin group media relations
+ 33 1 45 66 22 22
X : @MichelinNews

Danone:
press@danone.com

DMC Biotechnologies:
Kathryn Sheridan
kathryn@dmcbio.com

Crédit Agricole Centre France:
Isabelle Dugat
isabelle.dugat@ca-centrefrance.fr
+33 4 73 30 58 89

About the Center for Sustainable Materials
The Center for Sustainable Materials is one of the four centers of Parc Cataroux, the only regeneration project of its kind in Europe dedicated to innovation in all its forms. Its aim is to develop circular supply chains with controlled impact in the field of bio-sourced or recycled materials. The Center for Sustainable Materials provides its ecosystem with its expertise and the facilities adjacent to the Michelin Cataroux site, to ensure the conditions for a successful industrial demonstrator for the startups that it hosts. Its infrastructure is funded by a property company composed of five partners: Crédit Agricole Centre France, the Michelin group, Banque des Territoires, Caisse d’Epargne Auvergne Limousin and the Puy-de-Dôme Clermont Auvergne Métropole Chamber of Commerce and Industry.

About Michelin
Michelin is building a world-leading manufacturer of life-changing composites and experiences. Pioneering engineered materials for more than 130 years, Michelin is uniquely positioned to make decisive contributions to human progress and to a more sustainable world.

Drawing on its deep know-how in polymer composites, Michelin is constantly innovating to manufacture high-quality tires and components for critical applications in demanding fields as varied as mobility, construction, aeronautics, low-carbon energies, and healthcare.

The care placed in its products and deep customer knowledge inspire Michelin to offer the finest experiences. This spans from providing data- and AI-based connected solutions for professional fleets to recommending outstanding restaurants and hotels curated by the MICHELIN Guide.

Headquartered in Clermont-Ferrand, France, Michelin is present in 175 countries and employs 132,200 people.

About Danone
Danone is a leading global food and beverage company operating in three health-focused, fast-growing and on-trend categories: Essential Dairy & Plant-Based products, Waters and Specialized Nutrition. With a long-standing mission of bringing health through food to as many people as possible, Danone aims to inspire healthier and more sustainable eating and drinking practices while committing to achieve measurable nutritional, social, societal and environment impact. Danone has defined its Renew strategy to restore growth, competitiveness, and value creation for the long-term. With almost 90,000 employees, and products sold in over 120 markets, Danone generated €27.6 billion in sales in 2023. Danone’s portfolio includes leading international brands (Actimel, Activia, Alpro, Aptamil, Danette, Danio, Danonino, evian, Nutricia, Nutrilon, Volvic, among others) as well as strong local and regional brands (including Aqua, Blédina, Bonafont, Cow & Gate, Mizone, Oikos and Silk). Listed on Euronext Paris and present on the OTCQX platform via an ADR (American Depositary Receipt) program, Danone is a component stock of leading sustainability indexes including the ones managed by Moody’s and Sustainalytics, as well as the MSCI ESG Indexes, the FTSE4Good Index Series, Bloomberg Gender Equality Index, and the Access to Nutrition Index. Danone’s ambition is to be B-Corp certified at global level in 2025.

About DMC
DMC is a US-based company that develops and produces chemicals and ingredients using precision fermentation. DMC’s proprietary technology platform Dynamic Metabolic Control™ makes fermentation more standardized, robust, and predictable.

About Crédit Agricole Centre France
Bolstered by its 2,400 employees and 230 branches, Crédit Agricole Centre France is a responsible and purpose-driven bank, that serves its 900,000 clients. Operating in Allier, Cantal, Corrèze, Creuse and Puy-de-Dôme, it is committed each day to developing its region, where it is the leading bank, and supports the creation and development of companies and initiatives that ensure sustainable local employment.

Involved over the last 20 years in investment capital, Crédit Agricole Centre France currently assists more than 50 companies with their development, transmission and external growth initiatives.

Strongly committed to fostering innovation, it also supports young, innovative companies thanks to its accelerator, the Village by CACF.

The post Danone, DMC, Michelin and Crédit Agricole Centre France join forces to create a cutting-edge biotechnology platform appeared first on DMC Biotechnologies.

The research and development lab employs a team of metabolic engineers, precision fermentation specialists, automation experts, and analytical support. The facility is home to DMC’s workflows in strain and metabolic engineering, high throughput testing, as well as bench and pilot scale fermentation. The RTP facility compliments DMC’s Boulder facility, which manages the company’s downstream separation and purification development activities.

DMC’s precision fermentation bioprocesses, which leverage its proprietary Dynamic Metabolic Control™ technology, enables the production of low carbon and economical chemicals. Improving the sustainability of chemicals is critical to mitigating future climate change.

Kenny Erdoes, DMC CEO said, “We are proud to announce the opening of our new laboratory in North Carolina. This new facility will support a growing team and enable us to bring online additional capabilities and streamline existing workflows to accelerate the development of new sustainable chemical solutions.”

North Carolina currently ranks among the top three U.S. states for bioscience employment and is a leader in vaccine research and manufacturing.

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com
ks@sustainabilityconsult.com

About DMC
DMC is a US bio-based chemical company that makes sustainably produced bio-based chemicals using
microbial fermentation. DMC’s proprietary Made to Scale™ technology platform makes fermentation
more standardized, robust, and predictable, transforming how the world makes chemicals.
DMC’s technology platform addresses the key barriers that have plagued the biotech industry for
decades including standardization, robustness, and predictability across scale. Addressing these
challenges translates to a dramatic reduction in the time to market and the investment needed to bring
products to commercialization.

For more information, visit: www.dmcbio.com

The post DMC opens new lab in Research Triangle Park, NC – New 9,500 Square Foot R&D Facility appeared first on DMC Biotechnologies.

The post Made to Scale™: How DMC is solving the historical challenges of biomanufacturing appeared first on DMC Biotechnologies.

Rusty Pittman, VP of Business Development, will pitch DMC’s precision fermentation technology and lead products at the event. DMC’s technology has been proven to address key barriers in the field and is the only approach that is Made to Scale™. This fits well with P&G’s approach to sustainable innovation because it is rooted in science, enables superior sustainability, and strengthens their supply chains to ensure business continuity in these increasingly volatile times.

The event is part of the “Cleaner, Better Together” programme that has been launched by P&G’s Fabric and Home Care division last year and aims to promote joint value creation by driving irresistible and sustainable superiority in partnership with top suppliers.

“P&G Fabric and Home Care are on a mission to decarbonize laundry while delighting consumers with irresistible superior product performance. We already have strong partnerships in place, but we don’t have all the answers yet, which is why we are calling on all moonshot thinkers – inventors, innovators, academics, start-ups, big and small companies – to help us innovate. The Supplier Summit in Brussels gives us, and our suppliers, a great opportunity to connect with potential new partners that could help us decarbonize the entire supply chain,” said Sundar Raman, Fabric and Home Care CEO.

DMC is thrilled to have been recognized as one of the select moonshot thinkers and we are looking forward to forming connections with P&G Fabric Care and their suppliers at this important summit.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Decarbonizing consumer goods requires scale. DMC has the only technology platform that is Made to Scale™. P&G is a household name in Home Care and provides access to massive channel scale for their products. We’re pleased to have the opportunity to showcase our products and technology as part of the P&G Supplier Summit and look forward to building end-to-end supply chains that deliver on scale, decarbonization, and exceeding customer expectations.”

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com
ks@sustainabilityconsult.com

About DMC
DMC is a US bio-based chemical company that makes products using microbial fermentation. DMC’s proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable.

DMC’s technology platform addresses the key barriers that have plagued the biotech industry for decades including standardization, robustness, and predictability across scale. Addressing these challenges translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.

For more information, visit: www.dmcbio.com

The post DMC invited by P&G Fabric and Home Care to pitch how precision fermentation can accelerate the journey to net zero by 2040 appeared first on DMC Biotechnologies.